FILTER BY SCHOLARAll Scholars
- The following scholars have published material in this field
FILTER BY RELEVANCEMost Recent
FILTER BY CONTENT TYPEAll Content Types
Writing in the New York Times Magazine last Sunday, computer science graduate student Yiren Lu offered an unusually eloquent and nuanced account of today’s Silicon Valley start-up scene.
If greater ownership of health data leads us to feel a greater sense of ownership of our health, a sense that we have the ability not only to maintain our health information, but also to influence, through our behavior, the data that’s collected – what a powerful and beneficial transformation this could be.
The challenges of moving a health-related technology from promise to impact are illustrated nicely by two recent attempts to carefully evaluate the benefits of intriguing new devices.
A new regulation proposed by the Food and Drug Administration will compel generic drug makers to update their labels to reflect “new” safety issues. This new rule is a poor tool for keeping generic drug labels up-to-date, and it will come at a significant cost to consumers. If public health is the true imperative for this change, the FDA can address the generic labeling issues in far better ways.
As busy as the digital health space has been lately, one group of stakeholders has been conspicuously absent from the proceedings: pharma companies. Shame on anyone who is surprised.
For the last five years or so, digital health has been the Rodney Dangerfield of investment sectors, getting more attention than respect, and garnering more page views than dollars.
Please join AEI as the chief actuary for Medicare summarizes the report’s results, followed by a panel discussion of what those spending trends are likely to mean for seniors, taxpayers, the health industry, and federal policy.
Please join us as four of Washington’s most distinguished political observers will revisit the Watergate hearings and discuss reforms that followed.